| Name | Title | Contact Details |
|---|
The Helper Bees is a technology platform focused on enhancing the aging-in-place experience for older adults in the healthcare sector. Founded in 2015 and based in Austin, Texas, the company operates across all 50 U.S. states, Washington D.C., and Puerto Rico. It offers a wide range of non-medical in-home care services, including home care, home modifications, pest control, and meal delivery, all facilitated through its Aging-In-Place Provider Network. The platform features several tools to ensure quality care, such as automatic fulfillment that monitors service quality, digital invoicing and payment systems, and digital claims tools to streamline processes and improve data collection. Additionally, the company provides care concierge services to help individuals navigate their supplemental benefits and manage payments. The Helper Bees partners with major insurance carriers and health plans to improve in-home care delivery and reduce healthcare costs, making aging in place more accessible for seniors and their families.
Cloud Giants provides consulting services to midsize B2B organizations in the Salesforce ecosystem looking to accelerate revenue operations. Through a unique blend of Salesforce expertise, technical proficiency and business acumen, we drive results and influence meaningful KPIs aligned to your business objectives. Cloud Giants specializes in: Increasing the velocity of revenue operations Reducing friction in the selling process Providing process transparency to all teams involved in the revenue lifecycle Simplifying and automating business processes Enhancing and streamlining the buyer experience Minimizing technical debt and delivering quicker time to value Our expertise includes Revenue Cloud/CPQ, Sales Cloud, and Experience Cloud solutions.
Everest Discovery LLC is a WBENC-Certified Woman Business Enterprise, national eDiscovery, Digital Forensics, and Litigation Support provider, headquartered in Philadelphia, PA with additional team members in the central and western states. Our organization has extensive experience supporting the litigation needs of major corporations and law firms. Through leading technology solutions and experienced personnel, Everest is positioned to support our clients across all phases of the Electronic Discovery Reference Model (EDRM). We believe all successful projects require experienced planning, proactive thinking, and outstanding communication. Our core focus is delivering solutions that bring order to chaos and reduce litigation risk through the implementation of proven workflows and leading technologies. Our approach ensures clients have greater control over external spending by promoting cost transparency and predictability, to effectively manage budgeted and forecasted spending. Everests commitment to information security management is reinforced through our organizations ISO 27001:2013 certification.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.